BioStock: Idogen has reached milestone in clinical trial preparations

Idogen has optimised the GMP manufacturing process in order to maximise the treatment effect of the cell therapy IDO 8 in patients with haemophilia A. The extensive optimisation work is now completed and Idogen is thus approaching the first clinical study with IDO 8. The company is about to submit a clinical trial application to the Medical Products Agency and plans to initiate the study during the second quarter of 2022.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/12/idogen-has-reached-milestone-in-clinical-trial-preparations/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se